| Old Articles: <Older 7981-7990 Newer> |
|---|
 |
Pharmaceutical Executive
October 1, 2011 |
The Permanent Campaign The product launch has been transformed from a concentrated, all-out military assault to the subtle, persuasive art of electioneering.   |
Pharmaceutical Executive
October 1, 2011 |
Inside the Mind of the CEO Steve Collis, CEO of AmerisourceBergen discusses his agenda for retooling the drug distribution giant. |
Pharmaceutical Executive
October 1, 2011
William Looney |
The Gathering Profiles of 30 of the pharmaceutical industry's key influences of the last three decades. |
Pharmaceutical Executive
October 1, 2011 |
30 Years of Pharma: Perspective in Numbers, Part 2 Top 10 pharmaceutical companies by market share. |
Pharmaceutical Executive
October 1, 2011 |
30 Years of Pharma: Perspective in Numbers, Part 3 Top 10 generics companies. |
Pharmaceutical Executive
October 1, 2011 |
30 Years of Pharma: Perspective in Numbers Top 10 pharmaceutical products worldwide. |
Pharmaceutical Executive
October 1, 2011 |
The Enterprising CRO Josef von Rickenbach, President & CEO of Parexel continues to lead the company, which has morphed from functional service provider to full-service global organization. |
Pharmaceutical Executive
October 1, 2011 |
Sweden: Setting the Pace for Global Pharma On health system decentralization, regulatory convergence, drug detailing, promotion, patient information, the environment, value-based pricing, and the pursuit of cost-effectiveness, the Nordics have been true innovators over the past decades. |
Pharmaceutical Executive
October 1, 2011 |
Regulation and Reputation: Still Two Solitudes The pharmaceutical and biopharmaceutical industries will only be able to continue providing patients with safe and effective medicines if the price is affordable. This will involve changes in attitudes by the industry, regulators, politicians, and the public. |
Pharmaceutical Executive
October 1, 2011
William Looney |
Partnering with the New Players Carlos Morel has been closely associated with the Oswaldo Cruz Foundation from the start of his career and now holds a pivotal role in creating a new infrastructure to support translational research on diseases critical to Brazil and other emerging country markets. |
| <Older 7981-7990 Newer> Return to current articles. |
